Randomized Trial of Paclitaxel Plus Paraplatin Versus Cyclophosphamide Plus Paraplatin in the Treatment of Advanced Epithelial Ovarian Cancer

Abstract

Objective to compare the efficacy and toxicity of paclitaxel plus paraplatin with paraplatin plus cyclophosphamide in the treatment of the advanced epithelial ovarian cancer.

Main outcome measure Response rate, drug toxicity, recurrent rate and survival

Results The paclitaxel 150 mg./m2 plus paraplatin AUC 6 and cyclophosphamide 700 mg./m2 plus paraplatin AUC 6 achieved similar results in clinical complete response 63.8% and 66.7%, pathological complete response 76.0% and 75.0%, recurrence after pathological complete response 36.8% and 55.5% respectively (P>0.05). The median disease free survival in the pathological complete response group of paclitaxel plus paraplatin cannot be estimated, whereas 11.0 months of paraplatin plus cyclophosphamide. The mean disease free survival of two groups fell in 39.8 and 27.1 months (p=0.07). The overall mean survival achieved 36.1 and 35.2 months (p>0.05). The toxicity was similar in both arms, except myalgia/arthralgia and skin rash occurrence in paclitaxel plus paraplatin arm.

Conclusion Paclitaxel plus paraplatin comparing with cyclophosphamide plus paraplatin in the treatment of advanced epithelial ovarian cancer showed no significant difference in complete response, recurrence, disease free survival and median survival with the acceptable toxicity.